The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Optimizing lenalidomide therapy in NDMM with renal impairment: an analysis of the REMNANT trial
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the optimization of lenalidomide therapy in renal impairment, highlighting an analysis of the prospective REMNANT study (NCT04513639) in transplant-eligible newly diagnosed multiple myeloma (NDMM). Dr Schjesvold notes that this trial has shown that higher doses of lenalidomide are tolerable and result in a greater renal response compared to standard doses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
